Effects of Bifidobacterium bifidum G9-1 on Hypercholesterolemic and Obese Diabetic Animal Models
Hiroshi OHNO1*, Yoko ISHIHARA1, Teruhiko ARAI1, Hideki YAMAMURA1, Nagao TOTANI2 and Takashi UEDA2
Received January 22, 2004; Accepted for publication, April 9, 2004
Bifidobacterium bifidum G9-1 (BBG9-1) was administered orally to ExHC (Exogenously Hypercholesterolemic) rats, Wistar fatty rats and KK-Ay mice, and the effect on the lipids of the plasma and liver was found to be as follows. 1) BBG9-1 significantly reduced the levels of cholesterol and triglyceride in the plasma and liver of ExHC rats fed a cholesterol-enriched diet. In addition, the cholesterol level of low-density lipoprotein (LDL), and the cholesterol and triglyceride levels of very low-density lipoprotein/chylomicron (VLDL/CM) were lower in the BBG9-1 administered rats than in the control rats. 2) In Wistar fatty rats, BBG9-1 significantly decreased the levels of cholesterol and triglyceride in the liver but not those in the plasma. 3) In KK-Ay mice, BBG9-1 significantly reduced not only the levels of cholesterol and triglyceride in the plasma and liver, but also the plasma glucose level. These results suggest that BBG9-1 lowers elevated levels of blood lipids and/or hepatic lipids in hypertriglyceridemia, hypercholesterolemia and hyperglycemia.
Key words: Bifidobacterium bifidum; hypercholesterolemia; obese diabetes mellitus; probiotics; animal models
*Corresponding author. Mailing address: Nutrition Business Group, Nestle Japan Ltd., NYK Tennoz Building, 2-2-20, Higashi-Shinagawa, Shinagawa-ku, Tokyo 140-0002, Japan. Phone: +81-3-5769-6211. Fax: +81-3-5769-6290. E-mail: Yoichi.Fukushima@jp.nestle.com
Bioscience Microflora 23(3): 109-117, 2004